Ask
For Sample Copy @
https://www.coherentmarketinsights.com/insight/request-sample/1373
Market Dynamics
Major factor fueling growth of the Alzheimer’s drugs market is
large number of drugs in pipeline, which are expected to enter into
market by 2022. According to the study published by Translational
Research and Clinical Intervention in September 2017, there are 105
new drugs in pipeline, out of which 25 are in phase one, 52 in phase
two and 28 are in phase three. These new products has novel approach
such as immunotherapy to target amyloid beta, beta-site amyloid
precursor protein cleaving enzyme 1 inhibitors, tau aggregation
inhibitor, serotonin 5-HT6 receptor antagonist. Along with this there
is an increase amount of collaboration amongst companies for
developing drugs in joint effort, for instance in November 2017,
Novartis and Amgen, along with the Banner Alzheimer's Institute,
announced a collaboration to assess potential of the BACE1 inhibitor
CNP520 to prevent or delay symptoms of Alzheimer's disease. In 2016,
AstraZeneca and Eli Lilly and Company entered into worldwide
agreement to co-develop MEDI1814, an antibody selective for
amyloid-beta 42 (Aβ42), which is currently in Phase I trials, as a
potential disease-modifying treatment for Alzheimer’s disease.
These collaborations are expected to accelerate the development
process and bring efficiency in entire arena of operations. However,
failing of investigational candidate in late stage is expected to be
a huge setback in the current Alzheimer’s drugs market, for
instance in February 2017, an external data monitoring committee
warned that Merck & Co. terminated study of Alzheimer's candidate
verubecestat due to potential failure in a Phase II/III study.
Increasing prevalence of Alzheimer’s disease to drive growth of
the Alzheimer’s drugs market worldwide
Increasing prevalence and incidence of Alzheimer’s disease
worldwide is expected to drive the growth of Alzheimer’s disease
therapeutics market. According to World Alzheimer Report in 2016, an
estimated 46.5 million people were suffering from Alzheimer’s
disease and the number is projected to reach 50 million by 2017,
every three second there is new patient of Alzheimer’s disease
worldwide.
Increasing age and aging global population are major risk factors for
Alzheimer’s, which increase the disease incidence and provide
growth opportunity for Alzheimer’s treatment market. For instance,
according to World Population Prospects (WPP) published by United
Nations in 2017, an estimated 962 million people are of age 60 or
above, which accounted for 13 per cent of the global population. The
number is projected to reach 1.4 billion by 2030, growing with annual
rate of 3 percent.
Key Players - Alzheimer’s Drugs Market
Key players operating in Alzheimer’s drugs market include Pfizer,
Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co.
Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other
prominent players whose products are under clinical trials are Eli
Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics,
Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.
Detailed Segmentation:
Global Alzheimer’s Drugs Market, By Drugs:
• Donepezil
• Rivastigmine
• Galantamine
• Memantine
Global Alzheimer’s Drugs Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• e-Commerce
Browse
Full Report @
https://www.coherentmarketinsights.com/market-insight/alzheimers-drugs-market-1373
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment